Austin L. Good

The CA19-9 glycan is a viable target for CAR T cell therapy in pancreatic and other solid tumors.

BACKGROUND & AIMS Chimeric antigen receptor (CAR) T cell therapy for pancreatic ductal adenocarcinoma (PDAC) has been challenging, in part due to the paucity of tumor-specific cell-surface targets. Here, we explored the design feasibility and anti-tumor efficacy of CAR T cells recognizing the CA19-9 glycan, a tumor ant...